Summary
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
History
Hookipa was founded in 2012 to develop VIPER technology to develop cancer therapeutics. The company has since expanded its focus to include a range of innovative immunotherapeutic approaches and believes that it can have a huge impact on global health, including infectious diseases.
Mission
To develop safe and effective immunotherapeutic treatments to make a positive impact on global health.
Vision
Our vision is to enable us to put immunotherapeutics at the center of healthcare, and to make a real difference to the lives of everyone affected by chronic and infectious diseases.
Key Team
Mr. Andreas Bergthaler (Co-Founder)
Mr. Lukas Flatz (Co-Founder)
Ms. Christine D. Baker M.B.A. (Chief Operating Officer)
Dr. Klaus Orlinger Ph.D. (Chief Scientific Officer)
Ms. Marine Popoff (Communications & Investor Relations Mang.)
Mr. Matthew L. S. Beck (Exec. Director of Investor Relations)
Mr. Michael Szumera (Exec. Director of Communications)
Recognition and Awards
Hookipa Pharma has been recognized as one of the Top 50 Private Companies in Europe by Fierce BioTech in 2015 and was a finalist in the 2015 Global Health Innovator Awards for its contributions to global health.
References
